Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model
作者： Klaus Müller , Guido Henke , Sophie Pietschmann , Stefaan van Gool , Steven De Vleeschouwer
DOI: 10.1007/S11060-015-1844-8
关键词:
摘要: We aimed to compare two different salvage treatment strategies for relapsed high-grade glioma (HGG) patients by means of a new prognostic model. A simplified version the so-called HGG-Immuno RPA model estimates prognosis HGG and distinguishes three classes (I = good, II = intermediate, III = poor). The has been constructed with cohort 117 whose consisted re-operation followed dendritic cell vaccination (ReOP + DCV). However, using only predictors histology, age performance status, the simplified is basically independent from treatment. In present study we applied simplified model to the used to construct original and another 165 who underwent re-irradiation (ReRT) at relapse. Then, compared outcomes achieved treatments in each class. predicted good, intermediate poor 11, 31 75 ReOP + DCV 20, 39 106 ReRT cohort, respectively. Neither was superior other. groups 12-months survival rates were 73, 59 25 % after 72, 36 23 % ReRT, Being easy handle treatment, aforementioned useful therapeutic decisions. ReOP + DVC seem be equally effective. choice should based on expected side effects.
springer.com
core.ac.uk
narcis.nl参考文章(23)
Guido Henke, Frank Paulsen, Joachim P. Steinbach, Ute Ganswindt, Hana Isijanov, Rolf-Dieter Kortmann, Michael Bamberg, Claus Belka, Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie Und Onkologie. ,vol. 185, pp. 113- 119 ,(2009) , 10.1007/S00066-009-1969-9
Timothy Charles Ryken, Steven N. Kalkanis, John M. Buatti, Jeffrey J. Olson, The role of cytoreductive surgery in the management of progressive glioblastoma Journal of Neuro-oncology. ,vol. 118, pp. 479- 488 ,(2014) , 10.1007/S11060-013-1336-7
Michael Schemper, Terry L. Smith, A note on quantifying follow-up in studies of failure time Controlled Clinical Trials. ,vol. 17, pp. 343- 346 ,(1996) , 10.1016/0197-2456(96)00075-X
Thomas Hundsberger, Detlef Brügge, Paul M. Putora, Patrik Weder, Johannes Weber, Ludwig Plasswilm, Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas Journal of Neuro-oncology. ,vol. 112, pp. 133- 139 ,(2013) , 10.1007/S11060-013-1044-3
Patrick Royston, Douglas G Altman, External validation of a Cox prognostic model: principles and methods BMC Medical Research Methodology. ,vol. 13, pp. 33- 33 ,(2013) , 10.1186/1471-2288-13-33
Maximilian Niyazi, Axel Siefert, Silke Birgit Schwarz, Ute Ganswindt, Friedrich-Wilhelm Kreth, Jörg-Christian Tonn, Claus Belka, Therapeutic options for recurrent malignant glioma. Radiotherapy and Oncology. ,vol. 98, pp. 1- 14 ,(2011) , 10.1016/J.RADONC.2010.11.006
Johanna Quick, Florian Gessler, Stephan Dützmann, Elke Hattingen, Patrick N. Harter, Lutz M. Weise, Kea Franz, Volker Seifert, Christian Senft, Benefit of tumor resection for recurrent glioblastoma Journal of Neuro-Oncology. ,vol. 117, pp. 365- 372 ,(2014) , 10.1007/S11060-014-1397-2
Gary M. Clark, Susan G. Hilsenbeck, Peter M. Ravdin, Michele De Laurentiis, C. Kent Osborne, Prognostic factors: rationale and methods of analysis and integration. Breast Cancer Research and Treatment. ,vol. 32, pp. 105- 112 ,(1994) , 10.1007/BF00666211
Eli T. Sayegh, Taemin Oh, Shayan Fakurnejad, Orin Bloch, Andrew T. Parsa, Vaccine therapies for patients with glioblastoma Journal of Neuro-oncology. ,vol. 119, pp. 531- 546 ,(2014) , 10.1007/S11060-014-1502-6
Steven De Vleeschouwer, Hilko Ardon, Frank Van Calenbergh, Raf Sciot, Guido Wilms, Johannes van Loon, Jan Goffin, Stefaan Van Gool, Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination Cancer Immunology, Immunotherapy. ,vol. 61, pp. 2105- 2112 ,(2012) , 10.1007/S00262-012-1271-Z